

CURRICULUM VITAE (1/26)

Name: Jeffrey V. Ravetch

Date and Place of Birth: May 3, 1951; New York, New York

Citizenship: United States

Residence: 450 East 52nd Street, New York, NY 10022

Education:

June 1973 - **B.S.**, Yale University, New Haven, CT
June 1978 - **Ph.D.**, Laboratory of Genetics (N. Zinder and P. Model), The Rockefeller University, New York, NY
June 1979 - **M.D.**, Cornell University Medical College, New York, NY

Postdoctoral Training:

1979 - 1982 Laboratory of Molecular Genetics (P. Leder), NICHD, NIH, Bethesda, MD

Positions and Appointments:

1997- **Theresa and Eugene M. Lang Chair**, The Rockefeller University
1996- **Professor**, The Rockefeller University
1993 - 1996 **Adjunct Professor**, Department of Microbiology and Immunology, Jefferson Medical College and Jefferson Cancer Institute
1990 - 1996 **Attending**, Division of Hematologic Oncology, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases
1990 - 1996 **Member**, Division of Molecular Biology, Memorial Sloan-Kettering Cancer Center
Professor, Cornell University Medical College
1986 - 1990 **Associate Attending**, Division of Medical Oncology, Hematology-Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center
1986 - 1990 **Associate Member**, Division of Molecular Biology, Memorial Sloan-Kettering Cancer Center
Associate Professor, Cornell University Medical College
1984 - 1987 **Guest Investigator**, Laboratory of Cellular Physiology and Immunology, The Rockefeller University
1982 - 1986 **Assistant Member**, Division of Molecular Biology, Memorial Sloan-Kettering Cancer Center
Assistant Professor, Cornell University Medical College
1979 - 1982 **Research Associate**, Laboratory of Molecular Genetics, NICHD, National Institutes of Health
1973 - 1979 **Biomedical Fellow**, The Rockefeller University
1972 - 1973 **Teaching Assistant**, Dept. of Chemistry, Yale University

Honors and Awards:

NSF Summer Research Fellowships, 1971, 1972
Cum laude, Yale College, 1973
Charles E. Culpeper Fellow, 1983-1985
Pew Scholar, 1985-1989
Burroughs-Wellcome Award in Molecular Parasitology, 1986
Irma T. Hirschl/Monique Weill-Caulier Trust Career Scientist Award, 1986
Boyer Research Award, Memorial Sloan-Kettering Cancer Center, 1988
Kunkel Lecturer, Rockefeller University, 1996
NIH MERIT Award, 1997
Ecker Lecturer, Case Western Reserve University, 2000
Lee J. Howley, Jr. Award, 2004
AAI-Huang Foundation Meritorious Career Award, 2005
Member, National Academy of Sciences, 2006
William B. Coley Award, Cancer Research Institute, 2007
Member, Institute of Medicine, 2007
Fellow, American Academy of Arts and Sciences, 2008
Fellow, American Association for the Advancement of Science, 2008
R.E. Dyer Lecture, NIH, 2010
Grabar Lecture, French Society of Immunology, 2010
Gairdner International Award, 2012
Sanofi-Institut Pasteur Award, 2012
Heidelberg-Kabat Lecture, Columbia University, 2013
Fahey/Rose Founders Lecture, Clinical Immunology Society, 2013
Honorary doctorate Friedrich-Alexander-University Erlangen-Nuremberg, 2013
Josephson Lecture, Downstate Medical College, 2014
Wolf Prize in Medicine, 2015
Distinguished Lecturer, Academia Sinica, 2015
Benacerraf Lecture, Harvard Medical School, 2016
Ross Prize in Molecular Medicine, 2017
Robert Koch Award, 2018
William Paul Memorial Award, 2021
Max Cooper Prize in Immunology, 2025

Patents:

5,116,965-Methods of obtaining histidine-rich protein genes of plasmodia
5,723,593-Diagnostic assay for Charcot Marie Tooth disease type 1B
5,728,377-Methods and compositions Incorporating IP-10
5,824,487-Method for screening for targets for anti-inflammatory or anti-allergic agents.
5,876,927-Nucleic acid diagnostic assay for Charcot-Marie-Tooth Disease type IB
5,877,396-Mice mutant for Fc Receptors and method of treating autoimmune disease.
6,676,927-Animal model and methods for its use in the selection of cytotoxic antibodies
7,038,031-DNA encoding FcyR receptor protein on NK cells.
7,416,726-Enhancement of antibody-mediated immune responses
7,846,744-Methods of identifying anti-inflammatory compounds
8,470,318-Polypeptides with enhanced anti-inflammatory properties
8,470,321-Antibodies specific for the protofibril form of beta-amyloid protein

8,618,251-Fc mutants
8,815,237-Aglycosylated immunoglobulin mutant
9,134,310 Methods of identifying anti-inflammatory compounds
9,340,607-Antibodies specific for the protofibril form of beta-amyloid protein
9,481,724-hDC-SIGN binding peptides
9,587,025 Non-sialylated anti-inflammatory polypeptides
9,657,101 Fc mutants
9,845,358 Anti-inflammatory polypeptides
10,167,332 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties
10,300,127 Immune complex
10,479,838 Antibodies to CD40 with enhanced agonist activity

Other Activities:

National

Ad hoc member, Immunobiology Study Section, 1986-1990
Ad hoc member, Tropical Medicine and Parasitology Study Section, 1988-1990
Member, Allergy and Immunology Study Section, 1990-1994
Member, Blood Diseases Advisory Panel of The New York Community Trust, 1990-1996
Founder and Organizer (with D. Wirth and L. van der Ploeg), Annual Woods Hole Molecular Parasitology Meeting, 1990-1992
NIH Task Force on Immunology and Aging, 1994
Institute of Medicine, Nat'l Academy of Sciences, Committee on Malaria Vaccines, 1995
AAI, American Association of Immunologists, Public Affairs Committee, 2003-2005

Editorial

Advisory Editor, The Journal of Experimental Medicine
Transmitting Editor, International Immunology

Scientific Consulting and Advisory Boards

Avalo Therapeutics
Biohaven Pharmaceuticals
Nuvig Therapeutics
Jasper Therapeutics
Rhapsogen
Vir Biotherapeutics

Professional Memberships:

American Society for Biochemistry and Molecular Biology
American Society for Cell Biology
American Society for Clinical Investigation
Harvey Society
AAAS
AAI

Home Address: 450 East 52nd Street
New York, NY 10022

Tel. #: (917) 532-3609

Office Address: The Rockefeller University
1230 York Ave., Box 98
New York, NY 10021

Tel. #: (212) 327-7321

E-Mail: ravetch@rockefeller.ed

Military Services: 1979-1982 USPHS Surgeon (04)

Bibliography

1. **Ravetch, J.V.**, Gralla, J. and Crothers, D.M. (1974) Thermodynamic and kinetic properties of short RNA helices: the oligomer series A_nGCU_n . *Nucleic Acids Research* 1:109-127. PMC343329
2. **Ravetch, J.V.** and Jakes, K.S. (1976) Intact 3' end of 16S rRNA is not required for specific mRNA binding. *Nature* 262:150-153.
3. **Ravetch, J.V.**, Model, P. and Robertson, H.D. (1977) Isolation and characterization of the ϕ 174 ribosome binding sites. *Nature* 265:698-702.
4. **Ravetch, J.V.**, Horiuchi, K., and Model, P. (1977) Mapping of bacteriophage ϕ 1 ribosome binding sites to their cognate genes. *Virology* 81:341-351.
5. **Ravetch, J.V.**, Horiuchi, K. and Zinder, N.D. (1977) Nucleotide sequences near the origin of replication of bacteriophage ϕ 1. *Proc. Natl. Acad. Sci. USA* 74:4219-4222.
6. **Ravetch, J.V.**, Horiuchi, K. and Zinder, N.D. (1978) Nucleotide sequence of the recognition site for the restriction-modification enzyme of *Escherichia coli* B. *Proc. Natl. Acad. Sci. USA* 75:2266-2270. PMC392533
7. Horiuchi, K., **Ravetch, J.V.** and Zinder, N.D. (1978) DNA replication of bacteriophage ϕ 1 in vivo. *Cold Spring Harbor Symposium on Quantitative Biology*, Vol. 43.
8. **Ravetch, J.V.**, Horiuchi, K. and Zinder, N.D. (1979) DNA sequence analysis of the defective interfering particles of bacteriophage ϕ 1. *J. Mol. Biol.* 128:305-318.
9. **Ravetch, J.V.**, Ohsumi, M., Model, P., Vovis, G.F., Fischhoff, D. and Zinder, N.D. (1979) Organization of a hybrid between phage ϕ 1 and plasmid pSC101. *Proc. Natl. Acad. Sci. USA* 76:2195-2198. PMC383564
10. **Ravetch, J.V.**, Kirsch, I.R. and Leder, P. (1980) Evolutionary approach to the question of immunoglobulin heavy chain switching: Evidence from cloned human and mouse genes. *Proc. Natl. Acad. Sci. USA* 77:6734-6738. PMC350363
11. Korsmeyer, S.J., Hieter, P., **Ravetch, J.V.**, Poplack, D., Waldmann, T. and Leder, P. (1981) Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B cells. *Proc. Natl. Acad. Sci. USA* 78:7096-7100. PMC349202
12. Kirsch, I., **Ravetch, J.V.**, Kwan, S.-P., Max, E.E., Ney, R.L. and Leder, P. (1981) Multiple immunoglobulin switch region homologies outside the heavy chain constant region locus. *Nature* 292:585-587.
13. Siebenlist, U., **Ravetch, J.V.**, Korsmeyer, S., Waldmann, T. and Leder, P. (1981) Human immunoglobulin D segments encoded in tandem multigenic families. *Nature* 294:631-635.
14. **Ravetch, J.V.**, Siebenlist, U., Korsmeyer, S., Waldmann, T. and Leder, P. (1981) The structure of the human immunoglobulin μ locus: characterization of embryonic and rearranged J and G genes. *Cell* 27:583-591.
15. Korsmeyer, S.J., Arnold, A., Bakhshi, A., **Ravetch, J.V.**, Siebenlist, U., Hieter, P.A., Sharrow, S.O., LeBien, T.W., Kersey, J.H., Poplack, D.G., Leder, P. and Waldmann, T.A. (1983) Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T-Cell and B-Cell precursor origins. *J. Clin. Invest.* 71:301-313. PMC436868
16. Waldmann, T.A., Korsmeyer, S.J., Hieter, P.A., **Ravetch, J.V.**, Broder, S. and Leder, P. (1983) Regulation of the humoral immune response: from immunoglobulin genes to regulatory T cell networks. *Fed. Proc.* 42:2498-2503.
17. Shin, H.-S., Flaherty, L., Artzt, K., Bennett, D. and **Ravetch, J.V.** (1983) Inversion in the H-2 complex of t-Haplotypes in mice. *Nature* 306:380.
18. **Ravetch, J.V.**, Feder, R., Pavlovic, A. and Blobel, G. (1984) Primary structure and genomic organization of the histidine-rich protein of the malaria parasite *Plasmodium lophurae*. *Nature* 312:616.

19. **Ravetch, J.V.**, Kochan, J. and Perkins, M. (1985) Isolation of the gene for a glycophorin-binding protein implicated in erythrocyte invasion by a malaria parasite. *Science* 227:1593-1597.
20. Luster, A.D., Unkeless, J.C. and **Ravetch, J.V.** (1985) γ -interferon transcriptionally regulates an early-response gene with homology to platelet proteins. *Nature* 315:672-676.
21. Bakshi, A., Guglielmi, P., Siebenlist, U., **Ravetch, J.V.**, Jensen, J.P. and Korsmeyer, S.J. (1986) A DNA insertion/deletion necessitates an aberrant RNA splice accounting for a μ heavy chain disease protein. *Proc. Natl. Acad. Sci. USA* 83:2689-2693. PMC323365
22. Kochan, J., Perkins, M. and **Ravetch, J.V.** (1986) A tandemly repeated sequence determines the binding domain for an erythrocyte receptor binding protein of *P. falciparum*. *Cell* 44:689-696.
23. Pologe, L. and **Ravetch, J.V.** (1986) A chromosomal rearrangement in a *P. falciparum* histidine-rich protein gene is associated with the knobless phenotype. *Nature* 322:474-477.
24. Portnoy, D.A., Erickson, A.H., Kochan, J., **Ravetch, J.V.** and Unkeless, J.C. (1986) Cloning and characterization of a mouse cysteine proteinase. *J. of Biol. Chem.* 261:14697-14703.
25. **Ravetch, J.V.**, Luster, A., Weinshank, R., Kochan, J., Pavlovec, A., Portnoy, D., Hulmes, J., Pan, Y-C. and Unkeless, J. (1986) Structural heterogeneity and functional domains of murine immunoglobulin G Fc receptors. *Science* 234:718-725.
26. Luster, A., Jhanwar, S., Chaganti, R.S.K., Kersey, J., and **Ravetch, J.V.** (1987) Interferon-inducible gene maps to a chromosomal band associated with a (4;11) translocation in acute leukemia cells. *Proc. Natl. Acad. Sci. USA* 84:2868-2871. PMC304761
27. Pologe, L., Pavlovec, A., Shio, H. and **Ravetch, J.V.** (1987) Primary structure and subcellular localization of the knob-associated histidine-rich protein of *Plasmodium falciparum*. *Proc. Natl. Acad. Sci. USA* 84:7139-7143. PMC299245
28. Luster, A.D. and **Ravetch, J.V.** (1987) Genomic characterization of gamma-interferon-inducible gene (IP-10) and identification of an interferon-inducible hypersensitive-site. *Mol. Cell. Biol.* 7:3723-3731. PMC368020
29. Luster, A.D. and **Ravetch, J.V.** (1987) Biochemical characterization of a γ interferon inducible cytokine (IP-10). *J. Exp. Med.* 166:1085-1097.
30. Weinshank, R.L., Luster, A.D. and **Ravetch, J.V.** (1988) Function and regulation of a murine macrophage-specific IgG Fc receptor, Fc γ R-a. *J. of Exp. Med.* 167:1909-1925.
31. Luster, A.D., Weinshank, R.L. and **Ravetch, J.V.** (1988) Molecular and biochemical characterization of a novel γ -interferon-inducible protein. *J. of Biol. Chem.* 263:12036-12043.
32. Pologe, L.G. and **Ravetch, J.V.** (1988) Large deletions result from breakage and healing of *P. falciparum* chromosomes. *Cell* 55:869-874.
33. Perussia, B., Tutt, M.M., Qiu, W.Q., Kuziel, W.A., Tucker, P.W., Trinchieri, G., Bennett, M., **Ravetch, J.V.** and Kumar, V. (1989) Murine natural killer cells express functional Fc γ Receptor II encoded by the Fc γ R α gene. *J. Exp. Med.* 170:73-86
34. **Ravetch, J.V.** and Perussia, B. (1989) Alternative membrane forms of Fc γ RIII(CD16) on human natural killer cells and neutrophils: Cell-type specific expression of two genes that differ in single nucleotide substitutions. *J. Exp. Med.* 170:481-497.
35. Brooks, D., Qiu, W.Q., Luster, A.D. and **Ravetch, J.V.** (1989) Structure and expression of human IgG FcRII(CD32): Functional heterogeneity is encoded by the alternatively spliced products of multiple genes. *J. Exp. Med.* 170:1369-1385.
36. Kurosaki, T. and **Ravetch, J.V.** (1989) A single amino acid substitution in the GPI attachment domain is responsible for the alternative membrane anchoring of Fc γ RIII(CD16). *Nature* 342:805-807.
37. Pologe, L.G., de Bruin, D. and **Ravetch, J.V.** (1990) A and T homopolymeric stretches

- mediate a DNA inversion in *Plasmodium falciparum* which results in loss of gene expression. *Mol. Cell. Biol.* **10**:3243-3246. PMC360690
38. Qiu, W.Q., de Bruin, D., Brownstein, B.H., Pearce, R., and **Ravetch, J.V.** (1990) Organization of the human and mouse low-affinity FcγR genes: Duplication and Recombination. *Science* **248**:732-735.
 39. Perussia, B. and **Ravetch, J.V.** (1991) FcγRIII(CD16) on human macrophages is a functional product of the FcγRIII-2 gene. *Eur. J. Immunol.* **21**:425-429.
 40. Kurosaki, T., Gander, I. and **Ravetch, J.V.** (1991) A subunit common to an IgG Fc receptor and the T cell receptor mediates assembly through different interactions. *Proc. Natl Acad. Sci. USA*, **88**:3837-3841. PMC51548
 41. Seykora, J., **Ravetch, J.V.** and Aderem, A. (1991) Cloning and molecular characterization of the murine macrophage "68-kDa" protein kinase C substrate, and its regulation by bacterial lipopolysaccharide. *Proc. Natl Acad. Sci. USA*, **88**:2505-2509. PMC51261
 42. Pearce, R., Feinman, R. and **Ravetch, J.V.** (1991). Characterization of the promoter of the human gene encoding the high-affinity IgG receptor: Transcriptional induction by γ-interferon is mediated through common DNA response elements. *Proc. Natl Acad. Sci. USA*, **88**:11305-11309. PMC53123
 43. Kurosaki, T., Gander, I., Wirthmueller, U. and **Ravetch, J.V.** (1992). The α subunit of the Fc ϵ RI is associated with the FcγRIII on mast cells. *J. Exp. Med.*, **175**:447-451.
 44. Wirthmueller, U., Kurosaki, T., Murakami, M. and **Ravetch, J.V.** (1992). Signal transduction by FcγRIII(CD16) is mediated through the γ chain, *J. Exp. Med.*, **175**:1381-1390.
 45. Lanzer, M., de Bruin, D. and **Ravetch, J.V.** (1992). Transcription mapping of a 100 kb locus of *P. falciparum* identifies an intergenic region in which transcription terminates and reinitiates, *EMBO*, **11**:1949-1955. PMC556654
 46. Schenkman, S., Kurosaki, T. **Ravetch, J.V.**, and Nussenzweig, V. (1992) Evidence for the participation of the Ssp-3 antigen in the invasion of non-phagocytic mammalian cells by *Trypanosoma cruzi*, *J. Exp. Med.*, **175**:1635-1641.
 47. Lanzer, M., de Bruin, D. and **Ravetch, J.V.** (1992) A sequence element associated with the *Plasmodium falciparum* KAHRP gene is the site of developmentally regulated protein interactions, *Nucl. Acids Res.*, **20**:3051-3056. PMC312436
 48. de Bruin, D., Lanzer, M. and **Ravetch, J.V.** (1992) Characterization of yeast artificial chromosomes from *Plasmodium falciparum*: Construction of a stable, representative library and cloning telomeric DNA fragments, *Genomics*, **14**:332-339.
 49. Lanzer, M., de Bruin, D. and **Ravetch, J.V.** (1993). Cloning of a complete *Plasmodium falciparum* chromosome reveals transcriptional differences in polymorphic and conserved domains, *Nature*, **361**:654-657.
 50. Salcedo, T.W., Kurosaki, T., Kanakaraj, P., **Ravetch, J.V.** and Perussia, B. (1993) Physical and functional association of p56^{lck} with FcγRIIIA (CD16) in Natural Killer cells, *J. Exp. Med.*, **177**:1475-1480.
 51. Pearce, R.N., Feinman, R., Darnell, J.E., Jr., and **Ravetch, J.V.** (1993) IFN-γ induction of FcγRI transcription requires assembly of a complex which includes a 91 kDa DNA binding protein, *Proc. Natl. Acad. Sci., USA*, **90**:4314-4318. PMC46497
 52. Sarris, A., Broxmeyer, H., Wirthmueller, U., Karasavvas, N., Cooper, S., Lu, L., Krueger, J., and **Ravetch, J.V.** (1993) Human interferon-inducible protein 10: Expression and purification of recombinant protein demonstrate inhibition of early human hematopoietic progenitors, *J. Exp. Med.*, **178**:1127-1132.

53. Muta, T., Kurosaki, T., Sanchez, M., Misulovin, Z., Nussenzweig, M., and **Ravetch, J.V.** (1994) A 13 amino acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. *Nature*, 368:70-73.
54. Su, Y., Brooks, D., Li, L., Lepercq, J., Trofatter, J., **Ravetch, J.**, and Lebo, R. (1993) Peripheral myelin protein zero gene mutated in Charcot-Marie-Tooth type 1B patients, *Proc. Natl Acad. Sci., USA*, 90:10856-10860. PMC47877
55. de Bruin, D., Lanzer, M., and **Ravetch, J.V.** (1994) Conserved arrays of repetitive sequences in the subtelomeric regions of *Plasmodium falciparum* chromosomes promote genetic diversity. *Proc. Natl. Acad. Sci., USA*, 91:619-623. PMC43000
56. Takai, T., Li, M., Sylvestre, D., Clynes, R., and **Ravetch, J.V.** (1994) FcR γ chain deletion results in pleiotropic effector cell defects. *Cell*, 76:519-529.
57. Feinman, R., Qiu, W.Q., Pearse, R.N., Nikolajczyk, B.S., Sen, R., Sheffery, M., and **Ravetch, J.V.** (1994) PU.1 and an HLH family member contribute to the myeloid-specific transcription of the FcγRIIIA promoter. *EMBO*, 13:3852-3860. PMC395298
58. Sylvestre, D.L. and **Ravetch, J.V.** (1994) Fc receptors initiate the Arthus reaction: Redefining the inflammatory cascade. *Science*, 265:1095-1098.
59. Lanzer, M., Wertheimer, S.P., de Bruin, D. and **Ravetch, J.V.** (1994) Chromatin structure determines the sites of chromosome breakages in *Plasmodium falciparum*. *Nucl. Acids Res.*, 22:3099-3103. PMC310281
60. Lanzer, M., de Bruin, D., Wertheimer, S.P., and **Ravetch, J.V.** (1994) Transcriptional and nucleosomal characterization of a subtelomeric gene cluster flanking a site of chromosomal rearrangements in *Plasmodium falciparum*. *Nucl.Acids Res.*, 22:4176-82.
61. Clynes, R., and **Ravetch, J.V.** (1995) Cytotoxic antibodies trigger inflammation through Fc receptors. *Immunity*, 3:21-26. PMC331913
62. Rubio, J.P., Triglia, T., Kemp, D.J., de Bruin, D., **Ravetch, J.V.** and Cowman, A.F. (1995) A YAC contig map of *Plasmodium falciparum* chromosome 4; Transcriptional analysis and characterization of a DNA amplification between two recently separated isolates. *Genomics*, 26: 192-198.
63. Su, X-z, Heatwole, V., Wertheimer, S., Guinet, F., Herrfeldt, J.A., Peterson, D.S., **Ravetch, J.V.** and Wellems, T.E. (1995) The large diverse gene family *var* encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes. *Cell*, 82:89-100.
64. Park, S.Y., Arase, H., Wakizaka, K., Hirayama, N., Masaki, S., Sato, S., **Ravetch, J.V.** and Saito, T.(1995) Differential contribution of the FcRγ chain to the surface expression of the T cell receptor among T cells localized in epithelia: analysis of the FcRγ deficient mice. *Eur. J. Immun.*, 25(7):2107-10.
65. Economides, A.N., **Ravetch, J.V.**, Yancopolous, G.D. and Stahl, N (1995) Designer Cytokines: Targetting actions to cells of choice. *Science* 270: 1351-1353.
66. Li, M., Wirthmueller, U. and **Ravetch, J.V.** (1995) Reconstitution of human FcγRIII cell-type specificity in transgenic mice, *J. Exp. Med.*, 183: 1259-1263
67. Seykora, J.T., Myat, M.M. Allen, L-A, **Ravetch, J.V.** and Aderem, A. (1996) Molecular determinants of the myristoyl-electrostatic switch of MARCKS, *J. Biol.Chem.*, 271: 18797-802
68. Takai, T., Ono, M., Hikida, M., Ohmori, H. and **Ravetch, J.V.** (1996) Augmented humoral and anaphylactic responses in FcγRII-deficient mice, *Nature*, 379:346-349.
69. Sylvestre, D., Clynes, R., Ma, M., Warren, H., Carroll, M. and **Ravetch, J.V.**(1996) IgG

- mediated inflammatory responses develop normally in complement deficient mice, *J. Exp. Med.*, 184:2385-2392. PMC2196366
70. Sylvestre, D. and **Ravetch, J.V.** (1996) A dominant role for mast cell Fc receptors in the Arthus reaction, *Immunity*, 5: 387-390
 71. Ono, M., Bolland, S., Tempst, P. and **Ravetch, J.V.** (1996) The role of the inositol phosphatase SHIP in negative regulation of the immune system by the receptor FcγRIIB, *Nature* 383: 263-266.
 72. Heiken, H., Schulz, R.-J., **Ravetch, J.V.**, Reinherz, E. L., and Koyasu, S. (1996) T lymphocyte development in the absence of FcεRIγ subunit: analysis of thymic dependent and independent α-β and γ-δ pathways, *Eur. J. of Immunol.* 26:1935-1943.
 73. Vasovic, L.V., Dylla R., Clynes, R., **Ravetch, J.V.** and Nikolic-Zugic, J. (1997) Synergy between an antibody and CD8⁺ cells in eliminating an established tumor, *Eur. J of Immunol.*, 27:374-82.
 74. Miyajima, I., Dombrowicz, D., Martin, T. R., **Ravetch, J.V.**, Kinet, J.-P., and Galli, S. J. (1997) Systemic anaphylaxis in the mouse can be mediated largely through IgG₁ and FcγRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG₁ dependent passive anaphylaxis, *J. of Clin. Invest.* 99:901-914. 507898
 75. Dombrowicz, D., Flamand, V., Miyajima, I., **Ravetch, J. V.**, Galli, S. J., and Kinet, J.-P. (1997) Absence of FcεRIα chain results in upregulation of FcγRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between FcεRI and FcγRIII for limiting amounts of FcRβ and γ chains. *J. of Clin. Invest.*, 99:915-925. PMC507899
 76. Ono, M., Okada, H., Bolland, S., Yanagi, S., Kurosaki, T. and **Ravetch, J.V.** (1997) Deletion of SHIP or SHP-1 reveals two distinct pathways for inhibitory signaling, *Cell*, 90:293-301.
 77. Vora, K.A., **Ravetch, J.V.** and Manser, T. (1997) Amplified follicular immune complex deposition in mice lacking the Fc receptor γ-chain does not alter maturation of the B Cell response. *J. Immunol.* 159:2116-2124.
 78. Jankovic, D., Cheever, A.W., Kullberg, M.C., Wynn, T.A., Yap, G., Caspar, P., Lewis, F.A., Clynes, R., **Ravetch, J.**, and Sher, A. (1998) CD4⁺ T cell-mediated granulomatous pathology in schistosomiasis is down-regulated by a B lymphocyte-dependent mechanism requiring Fc receptor signalling. *J. Exp. Med.*, 187:619-629. PMC2212140
 79. Clynes, R., Takechi, Y., Moroi, Y., Houghton, A. and **Ravetch, J.V.** (1998) Fc Receptors are required in passive and active immunity to melanoma. *Proc. Nat'l Acad. Sci., USA*, 95:652-656. PMC18475
 80. Shores, E., Kawabe, K., Ono, M., Sommers, C.L., Tran, T., Liu, K., Udey, M., **Ravetch, J.** and Love, P.E. (1998) T cell development in mice lacking all TCR-β family members (β, 17, and FcεRIγ). *J. Exp. Med.*, 187:1093-1101. PMC2212212
 81. Clynes, R., Dumitru, C. and **Ravetch, J.V.** (1998) Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis. *Science* 279:1052-54..
 82. Yuan, R. Clynes, R., Oh, J., **Ravetch, J.V.** and Scharff, M.D. (1998) Antibody-mediated modulation of *Cryptococcus neoformans* infection is dependent on distinct Fc receptors and IgG subclasses. *J. Exp. Med.*, 187:641-648. PMC2212141
 83. Bolland, S., Pearce, R., Kurosaki, T. and **Ravetch, J.V.** (1998) SHIP modulates immune receptor responses by regulating membrane association of BTK. *Immunity*, 8:509-516.
 84. Okada, H., Bolland, S., Hashimoto, A., Kurosaki, M., Iino, M., **Ravetch, J.V.** and Kurosaki, T. (1998). Role of the inositol phosphatase SHIP in B cell receptor-induced Ca²⁺

- oscillatory response. *J. Immunol.* 161:5129-5132.
85. Suzuki, Y., Shirato, I., Okumura, K., **Ravetch, J.V.**, Takai, T., Tomino, Y., and Ra, C.S. (1998) Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis. *Kidney Int.* 54:1166-1174.
 86. Clynes, R., Maizes, J.S., Guinamard, R., Ono, M., Takai, T., and **Ravetch, J.V.** (1999) Modulation of immune complex-induced inflammation *in vivo* by the coordinate expression of activation and inhibitory Fc receptors. *J. Exp. Med.*, 189:179-185. PMC1887693
 87. Yuasa, T., Kubo, S., Yoshino, T., Ujike, A., Matsumura, K., Ono, M., **Ravetch, J.V.** and Takai, T. (1999) Deletion of FcγRIIB renders H-2^b mice susceptible to collagen-induced arthritis. *J. Exp. Med.*, 189:187-194. PMC1887699
 88. Kubagawa, H., Chen, C.-C., Ho, L., Shimada, T., Gartland, L., Mashburn, C., Uehara, T., **Ravetch, J.V.** and Cooper, M.D. (1999) Biochemical nature and cellular distribution of the Paired Immunoglobulin-like Receptors, PIR-A and PIR-B. *J. Exp. Med.* 189:309-317. PMC2192985
 89. Ujike, A., Ishikawa, Y., Ono, M., Yuasa, T., Yoshino, T., Fukumoto, M., **Ravetch, J.V.**, and Takai, T. (1999) Modulation of IgE-mediated systemic anaphylaxis by low affinity Fc receptors for IgG. *J. Exp. Med.*, 189:1573-1579.
 90. Pearce, R.N., Kawabe, T., Bolland, S., Kurosaki, T., and **Ravetch, J.V.** (1999) SHIP recruitment attenuates FcγRIIB induced B cell apoptosis. *Immunity* 10:753-760.
 91. Guinamard, R., Signoret, N., Masamichi, I., Marsh, M., Kurosaki, T. and **Ravetch, J.V.** (1999) B cell antigen receptor engagement inhibits SDF-1α chemotaxis and promotes PKC-induced internalization of CXCR4. *J. Exp. Med.* 189:1461-1466. PMC2193069
 92. Qin, D., Wu, J., Vora, K., **Ravetch, J.V.**, Szakal, A.K., Manser, T. and Tew, J.G. (2000) FcγRIIB on follicular dendritic cells regulates the B cell recall response. *J. Immunology*, 164:6268-6275.
 93. Nakamura, A., Yuasa, T., Ujike, A., Ono, M., Nukiwa, T., **Ravetch, J.V.** and Takai, T. (2000) FcγRIIB-deficient mice develop Goodpasture's Syndrome upon immunization with Type IV collagen: a novel murine model for autoimmune GBM disease. *J. Exp. Med.*, 191:899-905. PMC2195851
 94. Jimack, L.F., Reininger, L., Chicheportiche, Y., Clynes, R., **Ravetch, J.V.**, Honjo, T., and Izui, S. (1999) High pathogenic potential of low-affinity autoantibodies in experimental autoimmune hemolytic anemia. *J. Exp. Med.* 190:1689-1696. PMC2195740
 95. Clynes, R.A., Towers, T.L., Presta, L.G. and **Ravetch, J.V.** (2000) Inhibitory Fc receptors modulate *in vivo* cytotoxicity against tumor targets. *Nature Med.* 6:443-446.
 96. Guinamard, R., Okigaki, M., Schlessinger, J. and **Ravetch, J.V.** (2000) Absence of marginal zone B cells in Pyk-2 deficient mice defines their role in the humoral response. *Nature Immunology*, 1:31-35.
 97. Bolland, S. and **Ravetch, J.V.** (2000) Spontaneous autoimmune disease in FcγRIIB deficient mice results from strain-specific epistasis. *Immunity*, 13:277-285.
 98. Samuelsson, A., Towers, T. and **Ravetch, J.V.** (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. *Science*, 291:484-486.
 99. Hawiger, D., Inabe, K., Dorsett, Y., Guo, M., Mahnke, K., Rivera, M., **Ravetch, J.V.**, Steinman, R. and Nussenzweig, M. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions *in vivo*. *J. Exp. Med.* 194:769-779. PMC2195961
 100. Khalil, M., Inaba, K., Steinman, R., **Ravetch, J.** and Diamond, B. (2001) T cell studies in a

- peptide-induced model of systemic lupus erythematosus. *J. Immunol.*, **66**:1667-1674.
101. Bolland, S., Yim, Y-S., Tus, K., Wakeland, E.K. and **Ravetch, J.V.** (2002) Genetic modifiers of SLE in FcγRIIB^{-/-} mice. *J. Exp. Med.* **195**:1167-1174. PMC2193704
102. Kalergis, A. and **Ravetch, J.V.** (2002) Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. *J. Exp. Med.* **195**:1653-1659. PMC2193555
103. Trcka, J., Moroi, Y., Clynes, R.A., Goldberg, S.M., Bergtold, A., Perales, M-A., Ma, M., Ferrone, C.R., Carroll, M.C., **Ravetch, J.V.** and Houghton, A.N. (2002) Redundant and alternative roles for activating Fc Receptors and complement in an antibody-dependent model of autoimmune vitiligo. *Immunity*, **16**:861-868.
104. Green, S.K., Karlsson, M.C.I., **Ravetch, J.V.** and Kerbel, R.S. (2002) Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer. *Cancer Research* **62**:6891-6900.
105. Wang, C., Khalil, M., **Ravetch, J.** and Diamond B. (2003) The naive B cell repertoire predisposes to antigen-induced systemic lupus erythematosus. *J. Immunol.*, **170**:4826-4832.
106. Bruhns, P., Samuelsson, A., Pollard, J. and **Ravetch, J.V.** (2003) Colony stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. *Immunity*, **18**:573-581.
107. Karlsson, M.C.I., Guinamard, R., Bolland, S., Steinman, R.M. and **Ravetch, J.V.** (2003) Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. *J. Exp. Med.* **198**:333-340. PMC2194070
108. Zhang, Z., Zhang, M., **Ravetch, J.V.**, Goldman, C. and Waldmann, T.A. (2003) Effective therapy for a murine model of Adult T-cell Leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. *Blood*, **102**:284-288.
109. Zhang, Z., Zhang, M., Goldman, C., **Ravetch, J.V.** and Waldmann, T.A. (2003) Effective therapy for a murine model of Adult T-cell Leukemia with the humanized anti-CD52 monoclonal antibody, CAMPATH-1H. *Cancer Research*, **63**:6453-6457.
110. Muhlfeld, A.S., Segerer, S., Hudkins, K. Carling, M.D., Wen, M., Farr, A.G., **Ravetch, J.V.** and Alpers, C.E. (2003) Deletion of the fcγ receptor Iib in thymic stromal lymphopoietin transgenic mice aggravates membranoproliferative glomerulonephritis. *Am J Pathol.* **163**(3):1127-1136. PMC1868251
111. Turhan, A., Jenab, P., Bruhns, P., **Ravetch, J.V.**, Collier, B.S., and Frenette, P.S. (2004) Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes. *Blood*, **103**:2397-2400.
112. Uchida, J., Hamaguchi, Y., Oliver, J.A., **Ravetch, J.V.**, Poe, J.C., Haas, K.M. and Tedder, T.F. (2004) The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes Through Fc Receptor-Dependent Mechanisms During Anti-CD20 Antibody Immunotherapy. *J. Exp. Med.*, **199**(12):1659-1669. PMC2212805
113. Zhang, M., Zhang, Z., Garmestani, K., Goldman, C.K., **Ravetch, J.V.**, Brechbiel, M.W., Carrasquillo, J.A., and Waldmann, T.A. (2004) Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. *Cancer Res* **64**:5825-5829.
114. Moll, T., Nitschke, L., Carroll, M., **Ravetch, J.V.** and Izui, S. (2004) A Critical Role for FcγRIIB in the Induction of Rheumatoid Factors. *J. Immunology*, **173**:4724-4728.
115. McGaha, T., Sorrentino, B. and **Ravetch, J.V.** (2005) Restoration of tolerance in lupus by targeted inhibitory receptor expression. *Science*, **307**:590-593.
116. Fukuyama, H., Nimmerjahn, F. and **Ravetch, J.V.** (2005) The inhibitory Fcγ receptor

- modulates autoimmunity by limiting the accumulation of immunoglobulin G⁺ anti-DNA plasma cells. *Nature Immunology*, 6:99-106.
117. Dhodapkar, K.M., Kaufman, J.L., Ehlers, M., Banerjee, D.K., Bonvini, E., Koenig, S., Steinman, R.M., **Ravetch, J.V.** and Dhodapkar, M.V. (2005) Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody coated tumor cells. *Proc. Natl. Acad. Sci.* 102(8):2910-2915. PMC549508
 118. Olsson, M., Bruhns, P., Frazier, W.A., **Ravetch, J.V.** and Oldenburg, P-A. (2005) Platelet homeostasis is regulated by platelet expression of CD47 under normal conditions and in passive immune thrombocytopenia. *Blood*, 105(9):3577-3582. PMC1895021
 119. Nimmerjahn, F., Bruhns, P., Horiuchi, K. and **Ravetch, J.V.** (2005) FcγRIV: A novel FcR with distinct IgG subclass specificity. *Immunity*, 23:41-51.
 120. Boruchov, A.M., Heller, G., Concetta-Veri, M., Bonvini, E., **Ravetch, J.V.** and Young, J.W. (2005) Activating and inhibitory IgG Fc receptors mediate opposing effects on human dendritic cell function. *J. Clin. Invest.*, 115: 2914-23. PMC1201664
 121. Nimmerjahn, F. and **Ravetch, J.V.** (2005) Divergent immunoglobulin G subclass activity through selective FcR binding. *Science* 310: 1510-12
 122. Okazaki, T., Otaka, Y., Wang, J., Hiai, H., Takai, T., **Ravetch, J.V.** and Honjo, T. (2005) Hydronephrosis associated with antiurethelial and antinuclear autoantibodies in BALB/c-FcγR2b-/-Pdcd1-/- mice. *J. Exp. Med.* 202: 1643-8. PMC2212956
 123. Yamazaki, S., Patel, M., Harper, A., Bonito, A., Fukuyama, H., Pack, M., Tarbell, K., Talmor, M., **Ravetch, J. V.**, Inaba, K. and Steinman, R.M. (2006) Effective expansion of alloantigen-specific Foxp3⁺CD25⁺ CD4⁺ regulatory T cells by dendritic cells during the mixed leukocyte reaction. *Proc. Natl. Acad. Sci. USA* 103: 2758-63. PMC1413800
 124. Ehlers, M., Fukuyama, H., McGaha, T., Aderem, A. and **Ravetch, J.V.** (2006) TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b autoantibodies in SLE. *J. Exp. Med.* 203: 553-61. PMC2118244
 125. Kaneko, Y., Nimmerjahn, F., Madaio, M. and **Ravetch, J.V.** (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. *J. Exp. Med.* 203: 789-97. PMC2118246
 126. Zhang, M., Yao, Z., Zhang, Z., Garmestani, K., Goldman, C.K., **Ravetch, J. V.**, Janik, J., Brechbiel, M.W. and Waldmann, T.A. (2006) Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody HeFi-1, does not require activating Fc receptors. *Blood* 108: 705-710. PMC1895489
 127. Kaneko, Y., Nimmerjahn, F. and **Ravetch, J.V.** (2006) Anti-inflammatory activity of Immunoglobulin G resulting from Fc sialylation. *Science* 313:670-673
 128. Mackay, M., Stavevsky, A., Wang, T., Aranow, C., Li, M., Koenig, S., **Ravetch, J.V.** and Diamond, B. (2006) Selective dysregulation of the FcγRIIB receptor on memory B cells in SLE. *J. Exp. Med.* 203: 2157-64. PMC2118390
 129. Maltais, L.J., Lovering, R.C., Taranin, A.V., Colonna, M., **Ravetch, J.V.**, Dalla-Favera, R., Burrows, P.D., Cooper, M.D., and Davis, R.S. (2006) New nomenclature for Fc receptor-like molecules. *Nat Immunol* 7:431-432.
 130. Dhodapkar, KM, Banerjee, D, Connolly, J, Kukreja, A, Matayeva, E, Veri, MC, **Ravetch, JV**, Steinman, RM and Dhodapkar, MV (2007) Selective blockade of the inhibitory Fc{gamma} receptor (Fc{gamma}RIIB) in human dendritic cells and monocytes induces a type I interferon response program. *J. Exp. Med.* 204:1359-69. PMC2118610
 131. Nimmerjahn, F, Anthony, RM and **Ravetch, JV** (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. *Proc Natl Acad Sci U SA* 104:8433-7.

PMC1895967

132. Kowalewska J, Muhlfield AS, Hudkins KL, Yeh MM, Farr AG, **Ravetch JV**, Alpers CE.(2007) Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease. *Am J Pathol.* 170:981-9. PMC1864872
133. Wermeling, F., Chen, Y., Pikkarainen, T., Scheynius, A., Winqvist, O., Izui, S., **Ravetch, J. V.**, Tryggvason, K. and Karlsson, M. (2007) Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus. *J. Exp. Med.*, 204:, 2259-2265. PMC2118440
134. Nandakumar, K.S., Collin, M., Olsen, A., Nimmerjahn, F., Blom, A., **Ravetch, J.V.**, and Holmdahl, R. (2007) Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis. *Eur. J. Imm.* 37: 2973-2982.
135. Baudino, L., Nimmerjahn, F., Azeredo da Silveira, S., Martinez-Soria, E., Saito, T., Carroll, M., **Ravetch, J.V.**, Verbeek, J.S., and Izui, S. (2008) Differential contribution of three activating IgG Fc receptors (FcgammaRI, FcgammaRIII, and FcgammaRIV) to IgG2a- and IgG2b-induced autoimmune hemolytic anemia in mice. *J Immunol* 180:1948-1953.
136. McGaha, T.L., Karlsson, M.C., and **Ravetch, J.V.** (2008) Fc{gamma}RIIB Deficiency Leads to Autoimmunity and a Defective Response to Apoptosis in Mrl-MpJ Mice. *J Immunol* 180:5670-5679.
137. Anthony, R.M., Nimmerjahn, F., Ashline, D.J., Reinhold, V.N., Paulson, J.C. and **Ravetch, J.V.** (2008) A Recombinant IgG that Recapitulates the Anti-Inflammatory Activity of IVIG. *Science* 320:373-376. PMC2409116
138. Albert, H., Collin, M., Dudziak, D., **Ravetch, J.V.**, and Nimmerjahn, F. (2008) In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. *Proc Natl Acad Sci USA* 105:15005-15009. PMC2567483
139. Baudino, L., Nimmerjahn, F., Shinohara, Y., Furukawa, J., Petry, F., Verbeek, J.S., Nishimura, S., **Ravetch, J.V.**, and Izui, S. (2008) Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. *J Immunol* 181:4107-4112.
140. Schupf, N., Tang, M.X., Fukuyama, H., Manly, J., Andrews, H., Mehta, P., **Ravetch, J.**, and Mayeux, R. (2008) Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. *Proc Natl Acad Sci USA* 105:14052-14057. PMC2544577
141. Giorgini, A., Brown, H.J., Lock, H.R., Nimmerjahn, F., **Ravetch, J.V.**, Verbeek, J.S., Sacks, S.H., and Robson, M.G. (2008) FcgammaRIII and FcgammaRIV are indispensable for acute glomerular inflammation induced by switch variant monoclonal antibodies. *J Immunol* 181:8745-52. PMC2649421
142. Anthony, R.M., Wermeling, F., Karlsson, M.C., and **Ravetch, J.V.** (2008) Identification of a receptor required for the anti-inflammatory activity of IVIG. *Proc Natl Acad Sci USA* 105: 19571-8 Nov 26 e-pub. PMC 2604916
143. Otten, M.A., van der Bij, G.J., Verbeek, S.J., Nimerjahn, F., **Ravetch, J.V.**, Beelen, R.H., van de Winkel, J.G., and van Egmond, M. (2008) Experimental antibody therapy of liver metastases reveals functional redundancy between FcgammaRI and FcgammaRIV. *J Immunol* 181:6829-36.
144. Baudino, L., Shinohara, Y., Nimmerjahn, F., Furukawa, J., Nakata, M., Martinez-Soria, E., Petry, F., **Ravetch, J.V.**, Nishimura, S., and Izui, S. (2008) Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector

- functions. *J Immunol* 181:6664-9.
145. Sazinsky, S.L., Ott, R.G., Silver, N.W., Tidor, B., **Ravetch, J.V.** and Wittrup, K.D. (2008) Aglycosylated immunoglobulin G1 variants productively engage activating Fc receptors. *Proc. Natl. Acad. Sci. USA* 105:20167-72. PMC2629253
 146. Delgado, M.F., Coviello, S., Monsalvo, A.C., Melendi, G.A., Hernandez, J.Z., Batalle, J.P., Diaz, L., Trento, A., Chang, H.Y., Mitzner, W., **Ravetch, J.V.**, Melero, J.A., Irusta, P.M. and Polack, F.P. (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. *Nat. Med.* 15: 34-41. PMC2987729
 147. Scheid, J.S., Mouquet, H., Feldhahn, N., Seaman, M.S., Velinzon, K., Pietzsch, J., Ott, R.G., Anthony, R.M., Zebroski, H., Hurley, A., Phogat, A., Chakrabarti, B., Li, Y., Connors, M., Pereyra, F., Walker, B.D., Wardemann, H., Ho, D., Wyatt, R.T., Mascola, J.R., **Ravetch, J.V.**, and Nussenzweig, M.C. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV infected individuals. *Nature* 458:636-40. Epub 2009 Mar 15.
 148. Santiago-Raber, M.L., Amano, H., Amano, E., Baudino, L., Otani, M., Lin, Q., Nimmerjahn, F., Verbeek, J.S., **Ravetch, J.V.**, Takasaki, Y., Hirose, S., and Izui, S. (2009) Fcγ receptor-dependent expansion of a hyperactive monocyte subset in lupus-prone mice. *Arthritis Rheum.* 60:2408-17.
 149. Abboud, N., Chow, S-K, Saylor, C. **Ravetch, J. V.**, Scharff, M.D. and Casadevall, A. (2010) A requirement for FcγR in antibody-mediated bacterial toxin neutralization. *J. Exp. Med.*, 207:2395-405. PMC 2964574
 150. Mouquet, H., Scheid, J.F., Zoller, J.J. Krogsgaard, M., Ott, R.G., Shukair, S., Artyomov, M.N., Pietzsch, J., Connors, M., Pereyra, F., Walker, B.D., Ho, D.D., Wilson, P.C., Seaman, M.S., Eisen, H.N., Chakraborty, A.K. Hope, T.J., **Ravetch, J. V.**, Wardemann, H., and Nussenzweig, M.C. (2010) Polyreactivity increases the apparent affinity of anti-HIV antibodies by heterologation. *Nature* 467:537-8.
 151. Nimmerjahn, F., Lux, A., Alberg, H., Woigk, M., Lehmann, C., Dudziak, D., Smith, P., and **Ravetch, J.** (2010) Fcγ₄ deletion reveals its central role for IgG2a and IgG2b activity in vivo. *Proc. Natl. Acad. Sci. USA*, 107:19396-401. Epub 2010 Oct. 25. PMC 2984189
 152. Miletic, A.V., Anzelon-Mills, A.N., Mills, D.M., Omori, S.A., Pedersen, I.M., Shin, D.M., **Ravetch, J.V.**, Bolland, S., Morse, H.C. 3rd, and Rickert, R.C. (2010) Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. *J. Exp. Med*, 207:2407-2420. PMC 2964567
 153. Anthony, R.M., Kobayashi, T., Wermeling, F. and **Ravetch, J.V.** (2011) Intravenous Gamma Globulin Suppresses Inflammation through a Novel Th2 Pathway. *Nature*, 475:110-113. PMC Journal In Press.
 154. Li, F., and **Ravetch, J.V.** (2011) Inhibitory FcγR engagement drives adjuvant and anti-tumor activities of agonistic anti-CD40 antibodies. *Science*, 333:1030-1034. PMC 3164589
 155. Smith, P., DeLillo, D.J., Bournazos, S., Li, F. and **Ravetch, J.V.** (2012) A mouse model recapitulating human FcγR structural and functional diversity. *PNAS*, 109, 6181-6 published online 4/2/12. PMC Journal In Press.
 156. Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, **Ravetch JV**, Lycke NY (2011) Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant. *J Immunol.* 2011 Oct 1;187(7):3641-52. Epub 2011 Aug 31.

157. Li, F. and **Ravetch, J.V.** (2012) Apoptotic and anti-tumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. *PNAS*, 109, 10966-71 published online 6/18/12. PMC Journal In Press.
158. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio PM, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, **Ravetch JV**, Ploss A, Nussenzweig MC.(2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. *Nature*. 6;492(7427):118-22. Epub 2012 Oct 24.
159. Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, **Ravetch JV**, Ploss A, Nussenzweig MC (2012) A mouse model for HIV-1 entry. *Proc Natl Acad Sci U S A*. 109(39):15859-64. Epub 2012 Sep 10.
160. Sondermann, P., Pincetic, A., Maamary, J. Lammens, K. and **Ravetch, J. V.** (2013) A general mechanism for modulating immunoglobulin effector function. *Proc. Natl. Acad. Sci. USA*, 110(24):9868-72
161. Simpson, T.R., Li, F., Montalvo-Ortiz, W, Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C. Henry, J.Y., Yagita, H., Wolchok, J.D., Peggs,, K.S., **Ravetch, J.V.**, Allison, J.P. and Quezada, S.A. (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 antibody therapy against melanoma *JEM*, 210(9):1695-710
162. Gruell H, Bournazos S, **Ravetch JV**, Ploss A, Nussenzweig MC, Pietzsch J. (2013) Antibody and antiretroviral pre-exposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. *J. Virol*. 87(15):8535-44
163. Wermeling, F., Anthony,A., Brombacher, F. and **Ravetch, J.V.** (2013) Acute inflammation primes myeloid effector cells for anti-inflammatory STAT6 signaling. *Proc. Natl. Acad. Sci. USA* 110(33):13487-91
164. Bournazos, S., Chow, S-K., Abboud, N., Casadevall, A. and **Ravetch, J.V.** (2014) Human IgG Fc domain engineering enhances anti-toxin neutralizing antibody activity. *JCI*, 124:725-9
165. Li, F. and **Ravetch, J. V.** (2013) Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB co-engagement *in vivo*. *PNAS*, 110:19501-6
166. DiLillo, D.J., Tan, G.S., Palese,P. and **Ravetch, J.V.** (2014) Broadly neutralizing anti-HA stalk antibodies require FcγR interactions during protection from influenza challenge *in vivo*, *Nat. Med.* 20:143-51
167. Li F, Smith P, **Ravetch JV**. (2014) Inhibitory Fcγ receptor is required for the maintenance of tolerance through distinct mechanisms. *J. Immunol.* 192:3021-8
168. Ahmed AA, Giddens J, Pincetic A, Lomino JV, **Ravetch JV**, Wang LX, Bjorkman PJ. (2014) Structural characterization of anti-inflammatory Immunoglobulin G Fc proteins. *J. Mol Biol.* 426:3166-3179
169. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, Eisenreich TR, Liu C, Gazumyan A, Schaefer U, Furze RC, Seaman MS, Prinjha R, Tarakhovsky A, **Ravetch JV**, Nussenzweig MC. (2014) Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice. *Cell* 158:989-999
170. Bournazos, S, Klein, F, Pietzsch, J, Seaman, M, Nussenzweig, MC and **Ravetch, JV** (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for *in vivo* activity. *Cell* 158:1243-1253
171. DeLillo, D. and **Ravetch, J.V.** (2015) Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. *Cell*, 161:1035-45

172. Wang, T.T., Maamary, J., Schlesinger, S.J., Kramer, F., Palese, P. and **Ravetch, J.V.** (2015) Anti-HA Fc glycoforms determine influenza vaccine efficacy through Type II Fc receptor signaling. *Cell*, 162:160-9
173. Fiebiger, B-M., Maamary, J., Pincetic, A. and **Ravetch, J.V.** (2015) Protection in antibody and T cell mediated autoimmune diseases by anti-inflammatory IgG Fcs requires Type II FcRs. *PNAS*, 112:E2385-94.
174. Dahan, R., Sega, E., Engelhardt, J., Selby, M. Korman, A.J. and **Ravetch, J.V.** (2015) FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. *Cancer Cell*, 28(3):285-95
175. DiLillo DJ, Palese P, Wilson PC, **Ravetch JV.** (2016) Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. *J Clin Invest.* 2016 126:605-10
176. Lu C.L., Murakowski D.K., Bournazos S., Schoofs T., Sarkar D., Halper-Stromberg A., Horwitz J. A., Nogueira L., Golijanin J., Gazumyan A., **Ravetch J. V.**, Caskey M., Chakraborty A., Nussenzweig M.C. (2016) Enhanced clearance of HIV-1-infected cells by anti-HIV-1 broadly neutralizing antibodies *in vivo*. *Science*, 352:1001-4
177. Bournazos, S, Gazumyan, A, Seaman, M.S, Nussenzweig, M.C. and **Ravetch, J.V.** (2016) Bispecific anti-HIV-1 antibodies with enhanced breadth and potency. *Cell*, 165:1609-20
178. Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, **Ravetch JV.** (2016) Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement. *Cancer Cell*, 29:820-31
179. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Östling J, Dahan R, Harris RA, Rantalainen M, Klevebring D, Sund M, Brage SE, Fuxe J, Rolny C, Li F, **Ravetch JV**, Karlsson MC. (2016) Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. *Cell Rep.* 15:2000-11
180. Wang, T., Sewatanon, J., Memoli, M., Wammert, J., Bournazos, S., Bhaumik, S., Pinsky, B., Chokephaibulkit, K., Onlamoon, N., Pattanapanyasat, K., Taubenberger, J., Ahmed, R. and **Ravetch, J.V.**, (2017) Anti-dengue antibodies enhanced for FcγRIIIa binding determine disease severity. *Science*, 355: 395-398
181. Li T, DiLillo DJ, Bournazos S, Giddens JP, **Ravetch JV**, Wang LX (2017) Modulating IgG effector function by Fc glycan engineering. *Proc Natl Acad Sci U S A.* 114(13):3485-3490.
182. Maamary J, Wang TT, Tan GS, Palese P, **Ravetch JV.** (2017) Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. *Proc Natl Acad Sci U S A.* 114(38):10172-10177.
183. Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, **Ravetch JV**, Wittrup KD. (2017) Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human FcγRIIIa and FcγRIIIa. *J Mol Biol.* 2017 429:2528-2541.
184. Raz A, Serrano A, Lawson C, Thaker M, Alston T, Bournazos S, **Ravetch JV**, Fischetti VA. (2017) Lysibodies are IgG Fc fusions with lysin binding domains targeting *Staphylococcus aureus* wall carbohydrates for effective phagocytosis. *Proc Natl Acad Sci U S A.* 114:4781-4786
185. Knorr DA, Dahan R, **Ravetch JV.** (2018) Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. *Proc Natl Acad Sci U S A.*

186. Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, Sato N, DiLillo DJ, Bamford RN, **Ravetch** JV, Waldmann TA. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. *Proc Natl Acad Sci U S A*. 2018;115
187. Giddens JP, Lomino JV, DiLillo DJ, **Ravetch** JV, Wang LX. Site-selective chemoenzymatic glycoengineering of Fab and Fc glycans of a therapeutic antibody. *Proc Natl Acad Sci U S A*. 2018 115:12023-12027
188. Pradier L, Blanchard-Brégeon V, Bohme A, Debeir T, Menager J, Benoit P, Barneoud P, Taupin V, Bertrand P, Dugay P, Cameron B, Shi Y, Naimi S, Duchesne M, Gagnaire M, Weeden T, Travaline T, Reczek D, Khiroug L, Slaoui M, Brunel P, Fukuyama H, **Ravetch** J, Canton T, Cohen C. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). *Alzheimers Res Ther*. 2018 Nov 28;10(1):117. doi: 10.1186/s13195-018-0447-y.
189. Weitzenfeld P, Bournazos S, **Ravetch** JV. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways. *J Clin Invest*. 2019 Sep 3;129(9):3952-3962. doi: 10.1172/JCI128437.
190. Bournazos S, DiLillo DJ, Goff AJ, Glass PJ, **Ravetch** JV. Differential requirements for Fc γ R engagement by protective antibodies against Ebola virus. *Proc Natl Acad Sci U S A*. 2019 Sep 4. pii: 201911842. doi: 10.1073/pnas.1911842116. [Epub ahead of print]
191. Van Rompay KKA, Coffey LL, Kapoor T, et al. A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. *Proc Natl Acad Sci U S A*. 2020;117(14):7981-7989. doi:10.1073/pnas.2000414117
192. Borghi S, Bournazos S, Thulin NK, et al. FcRn, but not Fc γ Rs, drives maternal-fetal transplacental transport of human IgG antibodies. *Proc Natl Acad Sci U S A*. 2020;117(23):12943-12951. doi:10.1073/pnas.2004325117
193. Glasgow A, Glasgow J, Limonta D, et al. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2. *Proc Natl Acad Sci U S A*. 2020 Oct 22:202016093. doi: 10.1073/pnas.2016093117.
194. Bournazos S, Corti D, Virgin HW, **Ravetch** JV. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. *Nature*. 2020 Oct 8. doi: 10.1038/s41586-020-2838-z. PMID: 33032297
195. Schäfer A, Muecksch F, Lorenzi JCC, Leist SR, Cipolla M, Bournazos S, Schmidt F, Gazumyan A, Baric RS, Robbiani DF, Hatzioannou T, **Ravetch** JV, Bieniasz PD, Nussenzweig MC, Sheahan TP. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection *in vivo*. *J Exp Med*. 2021 Mar 1;218(3):e20201993. doi: 10.1084/jem.20201993. PMID: 33211088
196. Eisinger S, Sarhan D, Boura VF, Ibarlucea-Benitez I, Tyystjärvi S, Oliynyk G, Arsenian-Henriksson M, Lane D, Wikström SL, Kiessling R, Virgilio T, Gonzalez SF, Kaczynska D, Kanatani S, Daskalaki E, Wheelock CE, Sedimbi S, Chambers BJ, **Ravetch** JV, Karlsson MCI. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. *Proc Natl Acad Sci U S A*. 2020 Dec 15;117(50):32005-32016. doi: 10.1073/pnas.2015343117. Epub 2020 Nov 23. PMID: 33229588; PMCID: PMC7750482.
197. La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyski A, Micke P, **Ravetch** JV, Karlsson MCI, Sarhan D. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. *Cancer Res*. 2021 Feb 15;81(4):956-967. doi: 10.1158/0008-5472.CAN-20-1885. Epub 2020 Dec 8. PMID: 33293426.

198. Nimmerjahn F, **Ravetch JV**. Four keys to unlock IgG. *J Exp Med*. 2021 Mar 1;218(3):e20201753. doi: 10.1084/jem.20201753. PMID: 33600555; PMCID: PMC7888349.
199. Garriss CS, Wong JL, **Ravetch JV**, Knorr DA. Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. *Sci Transl Med*. 2021 *Sci Transl Med*. PMID: 34011627
200. Li C, Chong G, Zong G, Knorr DA, Bournazos S, Aytenfisu AH, Henry GK, **Ravetch JV**, MacKerell AD Jr, Wang LX. Site-Selective Chemoenzymatic Modification on the Core Fucose of an Antibody Enhances Its Fcγ Receptor Affinity and ADCC Activity. *J Am Chem Soc*. 2021 *JACS*
201. Bournazos S, Vo HTM, Duong V, Auerswald H, Ly S, Sakuntabhai A, Dussart P, Cantaert T, **Ravetch JV**. Antibody fucosylation predicts disease severity in secondary dengue infection. *Science*. 2021 Jun 4;372(6546):1102-1105. doi: 10.1126/science.abc7303. PMID: 34083490
202. Ibarlucea-Benitez I, Weitzenfeld P, Smith P, **Ravetch JV**. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. *Proc Natl Acad Sci U S A*. 2021 Jun 29;118(26):e2107424118. doi: 10.1073/pnas.2107424118. PMID: 34155121
203. Ou C, Li C, Zhang R, Yang Q, Zong G, Dai Y, Francis RL, Bournazos S, **Ravetch JV**, Wang LX. One-Pot Conversion of Free Sialoglycans to Functionalized Glycan Oxazolines and Efficient Synthesis of Homogeneous Antibody-Drug Conjugates through Site-Specific Chemoenzymatic Glycan Remodeling. *Bioconj Chem*. 2021 Aug 18;32(8):1888-1897. doi: 10.1021/acs.bioconjchem.1c00314. Epub 2021 Aug 5. PMID: 34351736
204. Yamin R, Jones A, Hoffmann HH, Kao K, Francis R, Sheahan T, Baric R, Rice C, **Ravetch, JV** and Bournazos S. Fc-engineered antibody therapeutics with improved efficacy against COVID-19. *Nature* (2021) 599, 465-470
205. Gupta A, Smith P, Bournazos S, **Ravetch JV**. A novel mouse strain optimized for chronic human antibody administration. *Proc Natl Acad Sci U S A*. 2022
206. Herati RS, Knorr DA, Vella LA, Silva LV, Chilukuri L, Apostolidis SA, Huang AC, Muselman A, Manne S, Kuthuru O, Staupe RP, Adamski SA, Kannan S, Kurupati RK, Ertl HCJ, Wong JL, Bournazos S, McGettigan S, Schuchter LM, Kotecha RR, Funt SA, Voss MH, Motzer RJ, Lee CH, Bajorin DF, Mitchell TC, **Ravetch JV**, Wherry EJ. PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. *Nat Immunol*. 2022 Aug;23(8):1183-1192.
207. Kao KS, Gupta A, Zong G, Li C, Kerschbaumer I, Borghi S, Achkar JM, Bournazos S, Wang LX, **Ravetch JV**. Synthetic nanobodies as tools to distinguish IgG Fc glycoforms. *Proc Natl Acad Sci U S A*. 2022 Nov 29;119(48).

208. Gupta A, Kao KS, Yamin R, Oren DA, Goldgur Y, Du J, Lollar P, Sundberg EJ, **Ravetch JV**. Mechanism of glycoform specificity and in vivo protection by an anti- afucosylated IgG nanobody. *Nat Commun*. 2023 May 18;14(1):2853.
209. Osorio JC, Smith P, Knorr DA, **Ravetch JV**. The Antitumor Activities of Anti-CD47 Antibodies Require Fc-Fc γ R interactions. *Cancer Cell* 2023, 41:2051-2065
210. Yamin R, Kao KS, MacDonald MR, Cantaert T, Rice CM, **Ravetch JV**, Bournazos S. Human Fc γ RIIIa activation on splenic macrophages drives dengue pathogenesis in mice. *Nat Microbiol*. 2023 Aug;8(8):1468-1479
211. Wong JL, Smith P, Angulo-Lozano J, Ranti D, Bochner BH, Sfakianos JP, Horowitz A, **Ravetch JV**, Knorr DA. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. *Proc Natl Acad Sci U S A*. 2023, 120:
212. Liu Y, Chen T, Zhu Y, Furey A, Lowary TL, Chan J, Bournazos S, **Ravetch JV**, Achkar JM. Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan. *JCI Insight*. 2023, in press
213. Knorr K, Rahman J, Erickson C, Wang E, Monetti M, Li Z, Ortiz-Pacheco J, Jones A, Lu SX, Stanley RF, Baez M, Fox N, Castro C, Marino AE, Jiang C, Penson A, Hogg SJ, Mi X, Nakajima H, Kunimoto H, Nishimura K, Inoue D, Greenbaum B, Knorr D, **Ravetch J**, Abdel-Wahab O. Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. *Nat Cancer*. 2023 , 4:1675-1692
214. Edgar JE, Trezise S, Anthony RM, Krammer F, Palese P, **Ravetch JV**, Bournazos S. Antibodies elicited in humans upon chimeric hemagglutinin-based influenza virus vaccination confer Fc γ R-dependent protection in vivo. *Proc Natl Acad Sci U S A*. 2023, 120:
215. Knorr D, Blanchard, L. Leidner R, Jensen S, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Sprott D, Bifulco C, Piening B, Dahan R, Fox BA, **Ravetch J**. Fc γ RIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies. *Cancer Immunology Research* 2024, 12:322-333
216. Osario, J, Smith, P, Knorr, D, **Ravetch J**., The anti-tumor activities of CD47 antibodies require Fc-Fc γ R interactions (2023) *Cancer Cell* 41:2051-2065
217. Osorio JC, Knorr DA, Weitzenfeld P, Blanchard, L., Yao N, Baez M, Sevilla, C., DiLillo M, Rahman J, Sharma, V., Bromberg J, Postow MA, Ariyan C, Robson ME, **Ravetch JV**.(2025) Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer. *Cancer Cell* 43:1902-1916
218. Wöhner M, Brechtelsbauer S, Friedrich N, Vorsatz C, Bulang J, Liang C, Schorr L, Beschin A, Guilleims M, **Ravetch J**, Nimmerjahn F, Biburger M (2024) Tissue niche occupancy determines the contribution of fetal- versus bone-marrow-derived macrophages to IgG effector functions. *Cell Rep*. 43:113757
219. Sastre DE, Bournazos S, Du J, Boder J, Edgar J, Azzam, T, Sultana N, Huliciak M, Flowers M, Yoza L, Xu T, Chernova TA, **Ravetch JV** and Sundberg EJ (2024) Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies *Cell*, 187: 6994-7007
220. Kao, K. Philstrom, N., Niejadik, E., Cantaert, T., Ahmed, R., **Ravetch, J.V.** and Bournazos, S. (2025) *PNAS*, 122:27
221. Jones, A. Martynyuk, T., Marino, A., Bournazos, S. and **Ravetch, J.V.** (2025) Enhancing the anti-inflammatory activity of IgG through co-engagement of type I and II Fc Receptors. *Science*, 390:6773
222. Sastre DE, Bournazos S, Huliciak M, Grace BAC, Boder EJ, Du J, Sultana N, Azzam T, Brown TJ, Flowers MW, Lollar P, Xu T, Chernova TA, Keith AD, Keen M, Saltzman A, Martinez Gascueña A, Trastoy B, Guerin ME, Frank F, Ortlund EA, **Ravetch JV**, Sundberg EJ (2025) The mechanistic basis for interprotomer deglycosylation of antibodies by corynebacterial IgG-specific endoglycosidases. *Nat Commun*.16:6147

223. Blanchard L, Vina E, Ljubetic J, Meneur C, Tarroux D, Baez M, Marino A, Ortega N, Knorr DA, **Ravetch JV**, Girard JP. (2025) Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade. *Cell Rep Med.* 2025 6:102141.
224. Azzam T, Bournazos S, Gunduz H, Adams T, Flowers MW, Niejadlik EG, Duong V, Brown TJ, Roberts AM, Sastre DE, Avci FY, Lam WA, Cantaert T, Roberts BR, Diamond B, **Ravetch JV**, Du, Sundberg, EJ (2025) Asymmetrically glycosylated IgG1 antibodies are universal and drive human disease. *Nat. Commun.*
225. Stark JC, Gray MA, Ibarlucea-Benitez I, Lustig M, Bond A, Cho B, Govil I, Luu T, Priestley MJ, Veth TS, Errington WJ, Bruncsics B, Ribí MK, Williams LA, Sarkar CA, Wisnovsky S, Riley NM, Morrissey MA, Valerius T, **Ravetch JV**, Bertozzi CR. (2025). Antibody-lectin chimeras for glyco-immune checkpoint blockade. *Nat. Biotech*

Chapters and Reviews

1. Korsmeyer, S.J., Hieter, P., **Ravetch, J.V.**, Poplack, D., Leder, P. and Waldmann, T.A. Pattern of immunoglobulin gene arrangements in human lymphocytic leukemias. In: Leukemia Markers (Knapp, W., ed.) 1981; Academic Press, London.
2. **Ravetch, J.V.**, Kirsch, I.R., Siebenlist, U. and Leder, P. Multiple somatic recombination events generate heavy chain immunoglobulin genes. In: Mechanism of Lymphocyte Activation, Proceedings of the 14th Leucocyte Culture Conference (Resch, K. and Kirschner, E., eds.) 1981; Elsevier/North Holland Press, Amsterdam.

3. Leder, P., Hieter, P., Hollis, G., Kirsch, I.R., Leder, P., Nau, M. and **Ravetch, J.V.** (1982) The new image of the mammalian genome. In: Perspectives on Genes and the Molecular Biology of Cancer (Robberson, D.L., Saunders, G.F., ed.) Raven Press.
4. Kirsch, I.R., **Ravetch, J.V.**, Hieter, P.A., Korsmeyer, S.J., Waldmann, T.A. and Leder, P. (1982) Genetic rearrangements in the humoral immune system. In: Current Concepts in Human Immunology and Cancer Immunomodulations (Serrou, B., ed.) Elsevier Biomedical Press B.V.
5. Waldmann, T.A., Korsmeyer, S.J., Hieter, P.A., **Ravetch, J.V.**, Arnold, A. and Leder, P. (1983) Immunoglobulin gene rearrangements in human lymphocytic leukemia. In: Recombinant DNA Applications to Human Disease, Banbury Report 14 (Caskey, C.T. and White, R.L., ed.) Cold Spring Harbor Press, N.Y.
6. **Ravetch, J.V.**, Young, J. and Poste, G. (1985) Molecular genetic strategies for the development of anti-malarial vaccines. *Biotechnology* 3:729-740.
7. Perkins, M., and **Ravetch, J.V.** (1985) Interaction of *Plasmodium falciparum* merozoite proteins with the erythrocyte surface. In: Vaccines, Cold Spring Harbor Laboratory Press, N.Y.
8. **Ravetch, J.V.** and Pologe, L.G. (1988) Molecular genetic strategies for parasite survival in *P. falciparum* malaria. In: Immunization (Root, Warren, Griffiss and Sande, eds.) Churchill Livingstone, Inc., New York, N.Y.
9. **Ravetch, J.V.** (1989) Chromosomal polymorphisms and gene expression in *Plasmodium falciparum*. *Exp. Parasitol.* 68:121-125.
10. **Ravetch, J.V.** and Anderson, C. (1989) Molecular diversity of FcγRs in Fc receptors and the action of antibodies chapter VI, ed. H. Metzger (American Society of Microbiology, Washington, D.C.).
11. **Ravetch, J.V.** and Kinet, J-P. (1991) Fc receptors. In: Annual Review of Immunology 9:457-92.
12. **Ravetch, J.V.** and Colton, H. (1992) Section editor: Innate Immunity in *Current Opinion in Immunology*, 4:1.
13. Lanzer, M., Wertheimer, S., de Bruin, D., and **Ravetch, J.** (1993) Plasmodium: Control of gene expression in malaria parasites. *Exp. Parasitol.* 77:121-128.
14. Lanzer, M., de Bruin, D., Wertheimer, S., and **Ravetch, J.V.** (1994) Organization of chromosomes in *Plasmodium falciparum*: A model for generating karyotypic diversity. *Parasitology Today*, 10:114-117.
15. Brooks, D. and **Ravetch, J.V.** (1994) Fc Receptor Signalling. In: Mechanisms of Lymphocyte Activation and Immune Regulation V, (Gupta, S., De Franco, A., Paul, W. and Perlmutter, R., ed.) Plenum Publishing, N.Y.
16. **Ravetch, J.V.** (1994) Atopy and Fc receptors: mutation is the message? *Nature Genetics*,
17. **Ravetch, J.V.** (1994) Fc Receptors: Rubor Redux. *Cell*, 78:553-560.
18. **Ravetch, J.V.** and Margulies, D.H. (1994) New tricks for old molecules. *Nature* 372:323-324.
19. **Ravetch, J.V.** and Colton, H. (1995) Section editor: Innate Immunity in *Current Opinion in Immunology*, 7:1-3.
20. **Ravetch, J.V.** (1997) Fc receptors. *Current Opinion in Immunology*, 9:121-125.
21. Vora, K.A., **Ravetch, J.V.** and Manser, T. (1997) Maturation of the B cell response in genetically altered mice. In: Developmental Immunology.
22. **Ravetch, J.V.** and Clynes, R.A. (1998) Divergent roles for Fc receptors and complement *in vivo*. In: Annual Review of Immunology, 16:421-32.
23. Bolland, S. and **Ravetch, J.V.** (1999) Inhibitory pathways triggered by ITIM-containing receptors. *Advances in Immunology*, 72:149-177.
24. **Ravetch, J.V.** and Lanier, L.L. (2000) Immune Inhibitory Receptors. *Science*, 290:84-89.

25. **Ravetch, J.V.** and Bolland, S. (2001) IgG Fc Receptors. In: Annual Review of Immunology, 19:275-90.
26. **Ravetch, J.V.** (2002) A full complement of receptors in immune complex diseases. *J. Clin. Invest.* 110:1759-1761.
27. **Ravetch, J.V.** (2003) Fc Receptors. In *Fundamental Immunology*, 5th edition, W. M. Paul, editor.
28. Steinman, R.M., Hawiger, D., Liu, K. Bonifaz, L., Bonnyay, D., Mahnke, K., Iyoda, T., **Ravetch, J.**, Dhodapkar, M., Inaba, K. and Nussenzweig, M. (2003) In: *Ann. N.Y. Acad. Sci.* 987:15-25.
29. **Ravetch, J.V.** and Carroll, M.C. (2004) Fc and Complement Receptors. In: Molecular Biology of B cells. ed. T. Honjo, F. Alt and M. Neuberger, chapter 18, pages 275-289.
30. Nimmerjahn, F. and **Ravetch, J.V.** (2006) Fcγ receptors: old friends and new family members. *Immunity* 24: 19-28
31. Ehlers, M. and **Ravetch, J.V.** (2006) Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. *Trends Immunol.* 28: 74-9.
32. Nimmerjahn, F. and **Ravetch, J.V.** (2007) The anti-inflammatory activity of IgG: the intravenous IgG paradox. *J. Exp. Med.*, 204: 11-15. PMC2118416
33. **Ravetch, J.V.** and Nimmerjahn, F. (2007) Fc Receptors. In *Fundamental Immunology*, chapter 22, 6th edition, W. M. Paul, editor.
34. Nimmerjahn, F. and **Ravetch, J.V.** (2007) Fc-receptors as regulators of immunity. *Adv Immunol* 96:179-204.
35. **Ravetch, J.V.** and Nussenzweig, MC (2007) Killing some to make way for others. *Nat Immunol.* 8:337-9
36. Nimmerjahn, F. and **Ravetch, J.V.** (2007) Antibodies, Fc receptors and cancer. *Curr Opin Immunol.* 19:239-45
37. **Ravetch, J.V.** and Aderem, A. (2007) Phagocytic cells. *Immunol. Rev.* 219: 5-7
38. Nimmerjahn, F. and **Ravetch, J.V.** (2008) Anti-Inflammatory Actions of Intravenous Immunoglobulin. *Annu Rev Immunol* 26:513-533.
39. Nimmerjahn, F. and **Ravetch, J.V.** (2008) Fcγ receptors as regulators of immune responses. *Nat Rev Immunol* 8:34-47.
40. Nimmerjahn, F. and **Ravetch, J.V.** (2008) Analyzing antibody-Fc-receptor interactions. *Methods Mol Biol* 415:151-162.
41. Nimmerjahn, F. and **Ravetch, J.V.** (2008) Fc Receptors. In *How the Immune System Recognizes Self and Nonself: Immunoreceptors and Their Signaling*, chapter 6, D. Kitamura, editor.
42. **Ravetch, J. V.** (2010) In vivo veritas: the surprising roles of Fc receptors in immunity. *Nature Immunology* 11:183
43. Anthony, R.M. and **Ravetch, J. V.** (2010) A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. *J. Clin. Immunol.* 30: Suppl 1:S9-14
44. Nimmerjahn, F. and **Ravetch, J. V.** (2010) Antibody-mediated modulation of immune responses. *Immunol. Rev.* 236:265
45. Nimmerjahn, F. and **Ravetch, J. V.** (2010) Fcγ receptors in Health and Disease. *Curr. Top. Microbiol. Immunol*
46. Anthony, R. M., Wermeling, F., and **Ravetch, J.** (2012) Novel roles for the IgG Fc glycan. In: *Ann. N.Y. Acad. Sci.* 1253:170-180
47. Li F, **Ravetch JV.** (2012) A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. *Cell Cycle.* 15;11(18):3343-4. Epub 2012 Aug 23.
48. Nimmerjahn F, **Ravetch JV.** (2012) Translating basic mechanisms of IgG effector activity into next generation cancer therapies. *Cancer Immun.* 12:13. Epub 2012 May 1.
49. Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebigier BM, **Ravetch JV.** (2014) Type I and type II Fc receptors regulate innate and adaptive immunity.

- Nat Immunol. 2014 Jul 21;15(8):707-716.
50. Bournazos, S., DiLillo, D. and **Ravetch, J.V.** (2014) Humanized mice to study FcR function. *Curr Top Microbiol Immunol.* 382:237-48.
 51. Wang, TT and **Ravetch, J. V.** (2015) Immune complexes: not just an innocent bystander in chronic viral infection. *Immunity.* 42:213-5.
 52. DiLillo DJ, **Ravetch JV.**(2015) Fc receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. *Cancer Immunol.* 3:704-13
 53. Bournazos S, DiLillo DJ, **Ravetch JV.** (2015) The role of Fc-FcR interactions in IgG-mediated microbial neutralization. *J Exp Med.* 212(9):1361-9.
 54. Bournazos S, **Ravetch JV.** (2015) Fc receptors pathways during active and passive immunization. *Immunol Rev.* 268:88-103
 55. Bournazos S, Wang TT, **Ravetch JV.** (2016) The Role and Function of Fcγ Receptors on Myeloid Cells. *Microbiol Spectr.* 24(6).
 56. Bournazos S, **Ravetch JV.** (2017) Anti-retroviral antibody FcγR-mediated effector functions. *Immunol Rev.* 275(1):285-295
 57. Bournazos S, **Ravetch JV.** (2017) Attenuated Vaccines for Augmented Immunity. *Cell Host Microbe.* 21(3):314-315
 58. Bournazos S, **Ravetch JV.** (2017) Fcγ Receptor Function and the Design of Vaccination Strategies. *Immunity.* 47:224-233.
 59. Bournazos S, **Ravetch JV.** (2017) Diversification of IgG effector functions. *Int Immunol.* 29(7):303-310
 60. Bournazos S, Wang TT, Dahan R, Maamary J, **Ravetch JV.** (2017) Signaling by Antibodies: Recent Progress *Annu Rev Immunol.* 35:285-311.
 61. Wang TT, Bournazos S, Ravetch JV. Immunological responses to influenza vaccination: lessons for improving vaccine efficacy. *Curr Opin Immunol.* 2018;53:124-129. doi:10.1016/j.coi.2018.04.026
 62. Knorr DA, Ravetch JV. Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism. *Clin Cancer Res.* 2019;25(3):904-906. doi:10.1158/1078-0432.CCR-18-3144
 63. Wang TT, Ravetch JV. Functional diversification of IgGs through Fc glycosylation. *J Clin Invest.* 2019;129(9):3492-3498. doi:10.1172/JCI130029
 64. Bournazos S, Gupta A, Ravetch JV. The role of IgG Fc receptors in antibody-dependent enhancement [published online ahead of print, 2020 Aug 11]. *Nat Rev Immunol.* 2020;1-11. doi:10.1038/s41577-020-004

Legal Consulting 2003 - present

- *Ariad Pharmaceutical. v. Eli Lilly & Co.*, No. 1:02-cv-11280-RWZ (D. Mass.)
- *University of Michigan v. Bristol-Myers Squibb Co.*, No. 2:06-cv-4-TJW (E.D. Tex.)
- *Talecris Biotherapeutics, Inc. v. Baxter International, Inc.*, No. 1:05-cv-00349-GMS (D. Del.)
- *ZymoGenetics, Inc. v. Bristol-Myers Squibb Co.*, No. 1:06-cv-00500-SLR (D. Del.)
- *Abbott Labs. v. Imclone Systems, Inc.*, No. 1:07-cv-10216-RGS (D. Mass)
- *Amgen, Inc. v. Ariad Pharmaceuticals, Inc.*, No. 1:06-cv-00259-MPT (D. Del.)
- *Amgen, Inc. v. Hoffman - LaRoche, Inc.*, No. 05-CV-12237-WGY (D. Mass.)
- *Abbott Labs v. Ortho Diagnostic Systems, Inc.*, Arbitration.
- *Inova Diagnostics, Inc. v. Euro-Diagnostica AB*, No. 3:08-cv-00845-H (S.D. Cal.)
- Appeal regarding EP 0614984, Appeal No. T0601/05 (European Patent Office).
- *Abbott Labs. v. Bayer Healthcare, LLC*, 09-40002-FDS (D. Mass.)
- *Bayer Healthcare, LLC v. Abbott Labs.*, No. 09-40061-FDS (D. Mass.)
- *Medimmune, LLC v. PDL Biopharma, Inc.*, Case No. CV 08 5590 JF (N.D. Cal.)
- *Novartis Vaccines and Diagnostics, Inc. v. Wyeth* Civil Action No. 2-08-cv-067 E.D. Texas
- *Keygene NV v. Floragenex, Inc.*
- *Novartis Vaccines and Diagnostics, Inc. v. Medimmune LLC*. Civil Action No. 1:11-CV-84-SLR (D. Del.)
- *Medimmune v. UMass, et al.* Civ. No. 351304V (Cir Court, Montgomery County) trial testimony
- *Bayer Healthcare v. Biogen Idec, Inc.* deposition
- *Regeneron v. Ablexis*: deposition
- *Regeneron v. Merus*; deposition and Markman testimony

- *GTG v. Agilent*, CASE NO. 3: 12-cv-0 1616-RS
- *Amgen v. Regeneron*, C.A. No.: 14-1317-SLR deposition, trial testimony
- **Forward Pharma v. Biogen** Interference No. 106,023 (McK) deposition
- **Kite Pharma** *Ex Parte* Reexamination of: U.S. Patent No. 7,741,465 B1
- *PDL v. Merck* C.A. No. 1:16-cv-00407-RMB-KMW deposition
- **Bayer Healthcare v. Baxalta, Nektar** C.A. No. 16-1122 (RGA) deposition, trial
- *Baxalta, Nektar v. Bayer Healthcare* C.A. No. 17-1316 (RGA) deposition
- **Teva Pharma v. Eli Lilly** C.A. 1:18-cv-12029-ADB deposition, trial
- *Celldex Therapeutics, INC v. SRS LLC*. C.A. No. 2020-0682-MTZ deposition
- *Amgen v. Sandoz* C.A. No. 1:23-cv-2406-CPO-EAP deposition, trial
- **Samsung Bioepis v. Alexion** IPR 2023-00933 deposition
- *Altor Bioscience v. HCW Biologics* JAMS No. 5220002288, deposition, hearing
- **Novartis v. Genentech** ICC Arbitration No. 27260/PDP deposition, hearing
- **Alnylam v. Pfizer**, C.A. No. 22-cv-336-CFC, deposition
- *PDL BioPharma, Inc. v. Eli Lilly and Company* C.A. 1:23-cv-02289-RLY-MKK, deposition

Scientific Consulting and Advisory Boards (past 10 years)

Asyria
Avalo (current)
Biohaven (current)
Compugen
Harpoon
Igenica
Jasper (current)
Janssen
Kleo
Medimmune
Merck BioVentures
Micromet
Momenta Pharmaceuticals, Inc.
Morphotek
MPM Capital
Nuvig (current)
Palleon
Portola Pharmaceuticals
Rhapsogen (current)
Sanofi
Seismic
Supremol
Takeda
Vir Biotherapeutics (current)
Virdante Pharmaceuticals
Xencor